🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 159 of 857 · Phase 3 first, then by program name

  1. Rifampicin

    United Therapeutics Europe Ltd

    Severe Acute Malnutrition

    phase 3 small molecule active

    1 trial

  2. Rifaximin

    Hospital Authority, Hong Kong

    Decompensated Cirrhosis

    phase 3 small molecule terminated

    1 trial

  3. Rifaximin

    The First People's Hospital of Lianyungang

    Crohn Disease

    phase 3 small molecule active

    1 trial

  4. Rilonacept

    Regeneron UK Limited

    Gout

    phase 3 mab completed

    3 trials

  5. Rilonacept

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 3 small molecule completed

    1 trial

  6. Rilonacept

    Regeneron UK Limited

    Acute Gout Flare

    phase 3 small molecule completed

    1 trial

  7. Rilonacept 80 mg

    Regeneron UK Limited

    Intercritical Gout

    phase 3 small molecule completed

    1 trial

  8. Rilotumumab

    Amgen

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  9. Riluzole

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  10. Rilvegostomig

    AstraZeneca

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  12. Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

  13. Rilzabrutinib

    Principia Biopharma, a Sanofi Company

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  14. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  15. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  16. Rimegepant

    Pfizer

    Migraine

    phase 3 small molecule active

    1 trial

  17. Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  18. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial

  19. Rina-S

    Genmab A/S

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  20. Riociguat

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Thromboembolic Pulmonary Hypertension

    phase 3 small molecule active

    1 trial

  21. Risankizumab

    AbbVie

    Psoriasis

    phase 3 small molecule active

    1 trial

  22. Risankizumab

    AbbVie

    Palmoplantar Pustulosis (PPP)

    phase 3 small molecule completed

    1 trial

  23. Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  24. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources